Source BioScience Launches Intelligent GenomeCUBE Search Engine
Source BioScience, the international laboratory services and products business, has launched an updated version of its GenomeCUBE search engine, an intelligent and powerful clone, antibody and protein products search and buying tool, which gives researchers easy access to millions of products, as well as Source BioScience’s scientific and technical support services.
Users can enter free text in GenomeCUBE, which interrogates public databases as well as Source BioScience’s own stores of clone libraries and individual clone sets, associated antibodies and kits. The tool also automatically provides a separate list, based on the results, for appropriate antibodies, reagents and kits. Searches can be based on clone identity, accession or other pertinent search terms such as species or cluster. The system now also includes protein databases, to identify gene related antibodies, reagents and kits all in one place.
The search engine enables researchers to access reference content on each of the products, including ‘real-time’ annotated information from multiple public databases. Users can purchase all products they require directly through GenomeCUBE, eliminating the need to search the internet for various providers.
Dr Nick Ash, CEO of Source BioScience, commented: “We have made a significant investment in developing the new infrastructure and search capabilities of GenomeCUBE. The tool now offers users an easier pathway from search to checkout and payment. Using GenomeCUBE researchers can access the information they need, the associated products they may require and proceed to purchase this in as few as three clicks. We believe the market needs a search engine of this type, to enable researchers to access millions of clones, hundreds of thousands of antibodies and the ability to purchase the reagents and kits from one source.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.